✦ LIBER ✦

Pharmacodynamic and pharmacokinetic comparison of two formulations of lorazepam and placebo

✍ Scribed by S. M. L. Abrams; T. V. A. Harry; A. Hedges; G. A. Murray; P. Turner

Publisher: John Wiley and Sons
Year: 1988
Tongue: English
Weight: 326 KB
Volume: 3
Category: Article
ISSN: 0885-6222
DOI: 10.1002/hup.470030210

No coin nor oath required. For personal study only.

✦ Synopsis

Nine healthy male volunteers took part in a comparison of the pharmacokinetic profiles and effects on psychomotor performance and memory following single dosing with an experimental sustained release (SR) and a conventional release (CR) formulation of lorazepam. There was evidence of a sustained release profile for the SR formulation which had a later tmar (median 8 h) and significantly lower peak serum concentrations (mean 12.1 ng m1-I) compared with CR lorazepam (2 h and 21.8 ng ml-' respectively). The effect of SR lorazepam on pharmacodynamic variables occurred later and was less intense than with CR lorazepam. Good correlations were obtained between most of the pharmacodynamic parameters measured and the logarithm of the serum concentration for both formulations, with the exception of the choice reaction time test for SR lorazepam. However, both formulations produced a similar degree of impairment of 24 h recall.

📜 SIMILAR VOLUMES

Pharmacokinetics of two lorazepam formul

Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses

✍ G. Caillé; J. Spénard; Y. Lacasse; J. Brennan 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB

The pharmacokinetic profiles of a sublingual and a conventional oral lorazepam tablet formulation were established following chronic administration to twelve healthy male volunteers. Fitting a multi-dose equation based on a one-compartment model to the observed data, the average elimination half-liv

Pharmacokinetic comparison of sublingual

Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam

✍ David J. Greenblatt; Marcia Divoll; Jerold S. Harmatz; Richard I. Shader 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 434 KB

Ten healthy volunteers received single 2-mg doses of lorazepam on five occasions in random sequence. Modes of administration were: A, intravenous injection; B, deltoid intramuscular injection; C, oral tablets in the fasting state; D, sublingual dosage of oral tablets in the fasting state; and E, sub

Pharmacokinetic-pharmacodynamic crossove

Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies

✍ Peter A. LeWitt; Danna Jennings; Kelly E. Lyons; Rajesh Pahwa; Adrian L. Rabinow 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

## Abstract Controlled‐release carbidopa and levodopa (CL‐CR) and the combination of carbidopa, levodopa, and entacapone (CLE) are used for extending levodopa (L‐dopa) effects. In a randomized, open‐label crossover study of 17 PD subjects with wearing‐off responses, we compared 8‐hour L‐dopa pharma

Comparative pharmacokinetics and pharmac

Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers

✍ Sonia Guimont; Dr Hélène Landriault; Keith Klischer; Michael Grace; Chantal Lamb 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 586 KB

CardizemOSR and Bi-TildiemO were both approved in their respective countries on the basis of clinical trials demonstrating efficacy and safety in the treatment of angina pectoris. In this cross-over randomized study, we assessed whether these two sustained-release formulations of diltiazem have equi

Pharmacokinetics and pharmacodynamics of

Pharmacokinetics and pharmacodynamics of azosemide

✍ Ok K. Suh; So H. Kim; Myung G. Lee 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB

Pharmacokinetics and pharmacodynamics of

Pharmacokinetics and pharmacodynamics of levodopa

✍ John G. Nutt 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

The pharmacokinetics and pharmacodynamics of levodopa are dominated by two features: the short plasma half-life of the drug and the portion of the antiparkinsonian response that parallels the plasma levodopa levels, the socalled short-duration response. These features are the basis of motor fluctuat